Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Results of Operations and Financial Condition

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On August7, 2018, Supernus Pharmaceuticals,Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter ended June30, 2018. A copy of this press release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.

As previously announced, Supernus will host a conference call at 9:00 a.m.Eastern Time on Wednesday, August8, 2018, to present the financial results. A live webcast will be available at webcast will be archived on the Company’s website for 60 days following the live call. Callers should dial in approximately 10 minutes prior to the start of the call. The phone number to join the conference call is +1 (877) 288-1043 (U.S. and Canada) or +1 (970) 315-0267 (international). The access code for the live call is 7484048.

The information in this Item 2.02 (including Exhibit99.1) is being “furnished” and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing.

This Current Report on Form8-K contains “forward-looking statements” that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as “believe,” “expect,” “intend,” “may,” “will,” “should,” or “anticipate” or similar terminology. All statements other than statements of historical facts included in this Current Report on Form8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form8-K. Except for Supernus’ ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form8-K are also subject to various risks and uncertainties, including those set forth in Item1A, “Risk Factors,” in Supernus’ Annual Report on Form10-K for the fiscal year ended December31, 2017, which the Company filed on March1, 2018 and the Quarterly Report on Form10-Q for the quarter period ended March31, 2018, which the Company filed on May10, 2018.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit to Item 2.02 hereof:

Exhibit99.1 – Press Release Dated August7, 2018.

EX-99.1 2 a18-18426_1ex99d1.htm EX-99.1 Exhibit 99.1     Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue   ·                  Total revenue of $99.5 million,…
To view the full exhibit click here

About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

An ad to help with our costs